Vimarsana
Biggest News Aggregation in the World

Page 4 - Thyroid Nodules News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Thyroid Nodules. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Thyroid Nodules Today - Breaking & Trending Today

The LUCA device proves its readiness for a better thyroid cancer screening - Vimarsana News

The LUCA device proves its readiness for a better thyroid cancer screening

 E-Mail IMAGE: First lab tests in 2019 of the LUCA device at ICFO research center in Barcelona. Dr. Mattia Squarcia tests the probe on a healthy patient to see the performance of... view more  Credit: ICFO Thyroid nodules are a common pathology having a prevalence of 19-76% when screened with ultrasound, with higher frequencies in women. Current medical methods used to assess the malignancy of a nodule consist in performing an ultrasound, followed by a Doppler ultrasound, and then a biopsy. However, unfortunately, these methods present both low specificity and low sensitivity. This ...

Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer - Vimarsana News

Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer

Published: Dec 21, 2020 ALAMEDA, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NASDAQ: EXEL) today announced that COSMIC-311, the phase 3 pivotal trial evaluating cabozantinib (CABOMETYX ®) versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after up to two prior vascular endothelial growth factor receptor (VEGFR)-targeted therapies, met the co-primary endpoint of demonstrating significant improvement in progression-free survival. Cabozantinib reduced the risk of disease progression or death by 78% with a hazard ratio of 0.22 (96% CI 0.13 ...

Detailed text transcripts for TV channel - FOXNEWS - 20120916:14:34:00 - Vimarsana News

Detailed text transcripts for TV channel - FOXNEWS - 20120916:14:34:00

Do that? >> it is point for doctors to be involved, if your doctors thinks so -- and the dha an epa, that is what is in fish and know the good stuff is in the fatty fish we are talking about and the salmon and mackerel and the sardines, you get the good stuff there. >> jamie: always better in food. >> if possible. >> eric: especially it is grilled. and, people diagnosed with thyroid disease, they say 27 million americans have thyroid disease, and, 13 million are undiagnosed. dr. samadi, how do you find out whether you have thyroid disease or not? >> well, you may have some subtle symptoms. you...